Abbott Laboratories' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Daclizumab, our next generation biologic for MS is in Phase III development. Our recently announced results from our Phase II registrational trial suggest that daclizumab may offer patients the right balance of high efficacy and a manageable safety ...
Abbott Reports Strong Ongoing Third Quarter Results; Confirms Double-Digit ...
Split News Overshadows Abbott Results
The Abbott Break-Up Seems To Make Sense (ABT, BIIB, BMY)